Study identifier:D3820C00006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2011-001985-16
CTIS identifier:N/A
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Relieving Opioid-Induced Constipation (OIC) in Patients with Cancer-Related Pain
Opioid-Induced Constipation
Phase 3
No
NKTR-118, Placebo
All
336
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Oct 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 (part A and B) Oral treatment | Drug: NKTR-118 12.5 mg oral tablet once daily |
Experimental: 2 (part A and B) Oral treatment | Drug: NKTR-118 25 mg oral tablet once daily |
Placebo Comparator: 3 (part A only) Oral treatment | Drug: Placebo Oral treatment |